BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005;42:1373-1381. [PMID: 16317693 DOI: 10.1002/hep.20935] [Cited by in Crossref: 372] [Cited by in F6Publishing: 320] [Article Influence: 23.3] [Reference Citation Analysis]
Number Citing Articles
1 Cadranel JD, Nousbaum J, Gouillou M, Hanslik B. Major changes in the number and indications of liver biopsy for chronic liver diseases over one decade in France: . European Journal of Gastroenterology & Hepatology 2016;28:e26-32. [DOI: 10.1097/meg.0000000000000683] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Li H, He Y, Di C, Yan J, Zhang H. Comparative analysis of the serum proteome for biomarker discovery to reveal hepatotoxicity induced by iron ion radiation in mice. Life Sci 2016;167:57-66. [PMID: 27815023 DOI: 10.1016/j.lfs.2016.10.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
3 Kim SY, Seok JY, Han SJ, Koh H. Assessment of liver fibrosis and cirrhosis by aspartate aminotransferase-to-platelet ratio index in children with biliary atresia. J Pediatr Gastroenterol Nutr. 2010;51:198-202. [PMID: 20531020 DOI: 10.1097/mpg.0b013e3181da1d98] [Cited by in Crossref: 56] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
4 Mao W, Sun Q, Fan J, Lin S, Ye B. AST to Platelet Ratio Index Predicts Mortality in Hospitalized Patients With Hepatitis B-Related Decompensated Cirrhosis. Medicine (Baltimore) 2016;95:e2946. [PMID: 26945406 DOI: 10.1097/MD.0000000000002946] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Myers RP, Elkashab M, Ma M, Crotty P, Pomier-Layrargues G. Transient elastography for the noninvasive assessment of liver fibrosis: a multicentre Canadian study. Can J Gastroenterol. 2010;24:661-670. [PMID: 21157581 DOI: 10.1155/2010/153986] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
6 Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol. 2010;10:103. [PMID: 20828377 DOI: 10.1186/1471-230x-10-103] [Cited by in Crossref: 83] [Cited by in F6Publishing: 42] [Article Influence: 7.5] [Reference Citation Analysis]
7 Castera L. Assessing liver fibrosis. Expert Rev Gastroenterol Hepatol. 2008;2:541-552. [PMID: 19072402 DOI: 10.1586/17474124.2.4.541] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.1] [Reference Citation Analysis]
8 Park SH, Bang CS, Kim DJ. Biomarkers in HCV Infection. Adv Clin Chem 2015;70:131-96. [PMID: 26231487 DOI: 10.1016/bs.acc.2015.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
9 Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology 2014;2014:1-15. [DOI: 10.1155/2014/357287] [Cited by in Crossref: 28] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
10 Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, Sotiropoulos GC, Paul A, Gerken G, Cicinnati VR. Assessment of Allograft Fibrosis by Transient Elastography and Noninvasive Biomarker Scoring Systems in Liver Transplant Patients. Transplantation 2010;89:983-93. [DOI: 10.1097/tp.0b013e3181cc66ca] [Cited by in Crossref: 53] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
11 Brady CW, Mchutchison JG, Patel K. Fibrosis markers in hepatitis C. Curr hepatitis rep 2006;5:86-93. [DOI: 10.1007/s11901-006-0010-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
12 Subasi CF, Aykut UE, Yilmaz Y. Comparison of noninvasive scores for the detection of advanced fibrosis in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015;27:137-141. [PMID: 25486027 DOI: 10.1097/meg.0000000000000255] [Cited by in Crossref: 26] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
13 Trinchet JC, Ganne-Carrié N, Nahon P, N'kontchou G, Beaugrand M. Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol 2007; 13(17): 2455-2460 [PMID: 17552029 DOI: 10.3748/wjg.v13.i17.2455] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
14 Boursier J, Konaté A, Gorea G, Reaud S, Quemener E, Oberti F, Hubert-Fouchard I, Dib N, Calès P. Reproducibility of liver stiffness measurement by ultrasonographic elastometry. Clin Gastroenterol Hepatol. 2008;6:1263-1269. [PMID: 18995217 DOI: 10.1016/j.cgh.2008.07.006] [Cited by in Crossref: 87] [Cited by in F6Publishing: 80] [Article Influence: 6.7] [Reference Citation Analysis]
15 Baranova A, Younossi ZM. The future is around the corner: Noninvasive diagnosis of progressive nonalcoholic steatohepatitis. Hepatology. 2008;47:373-375. [PMID: 18220279 DOI: 10.1002/hep.22140] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
16 Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Rousselet MC, Zarski JP, Calès P. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. BMC Gastroenterol. 2011;11:132. [PMID: 22129438 DOI: 10.1186/1471-230x-11-132] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
17 Lambrecht J, Verhulst S, Mannaerts I, Reynaert H, van Grunsven LA. Prospects in non-invasive assessment of liver fibrosis: Liquid biopsy as the future gold standard? Biochim Biophys Acta Mol Basis Dis. 2018;1864:1024-1036. [PMID: 29329986 DOI: 10.1016/j.bbadis.2018.01.009] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 8.0] [Reference Citation Analysis]
18 Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroentérologie Clinique et Biologique 2009;33:940-8. [DOI: 10.1016/j.gcb.2009.08.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
19 Dugum M, McCullough A. Diagnosis and Management of Alcoholic Liver Disease. J Clin Transl Hepatol 2015;3:109-16. [PMID: 26356792 DOI: 10.14218/JCTH.2015.00008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 14] [Article Influence: 5.8] [Reference Citation Analysis]
20 Lanquetin A, Leclercq S, de Timary P, Segobin S, Naveau M, Coulbault L, Maccioni P, Lorrai I, Colombo G, Vivien D, Rubio M, Pitel AL. Role of inflammation in alcohol-related brain abnormalities: a translational study. Brain Commun 2021;3:fcab154. [PMID: 34396111 DOI: 10.1093/braincomms/fcab154] [Reference Citation Analysis]
21 Boursier J, Isselin G, Fouchard-Hubert I, Oberti F, Dib N, Lebigot J, Bertrais S, Gallois Y, Calès P, Aubé C. Acoustic radiation force impulse: a new ultrasonographic technology for the widespread noninvasive diagnosis of liver fibrosis. Eur J Gastroenterol Hepatol. 2010;22:1074-1084. [PMID: 20440210 DOI: 10.1097/meg.0b013e328339e0a1] [Cited by in Crossref: 97] [Cited by in F6Publishing: 37] [Article Influence: 8.8] [Reference Citation Analysis]
22 Liu CH, Liu CJ, Hong CM, Su TH, Yang HC, Chen KM, Huang YP, Yeh YM, Tien HL, Liu YC, Kao JH, Chen DS, Chen PJ. A noninvasive diagnosis of hepatic fibrosis by BioFibroScore® in chronic hepatitis C patients. J Gastroenterol Hepatol 2018;33:291-7. [PMID: 28548299 DOI: 10.1111/jgh.13834] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
23 Caballería L, Torán P, Caballería J. Marcadores de fibrosis hepática. Medicina Clínica 2018;150:310-6. [DOI: 10.1016/j.medcli.2017.08.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
24 Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Rousselet MC, Zarski JP, Calès P. Comparison of accuracy of fibrosis degree classifications by liver biopsy and non-invasive tests in chronic hepatitis C. BMC Gastroenterol. 2011;11:132. [PMID: 22129438 DOI: 10.1186/1471-230x-11-132.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Cacoub P, Halfon P, Rosenthal E, Bailly F, Sadr FB, Benhamou Y, Chevaliez S, Pawlotsky JM, Piroth L, Yazdanpanah Y, Pol S. Care of hepatitis C virus infection in human immunodeficiency virus-infected patients: Modifications in three consecutive large surveys between 2004 and 2009. Journal of Hepatology 2010;53:230-7. [DOI: 10.1016/j.jhep.2010.03.009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
26 Vergniol J, de Ledinghen V. Diagnostic non invasif de la fibrose hépatique : modalités pratiques d’utilisation des marqueurs sanguins et du FibroScan. Gastroentérologie Clinique et Biologique 2009;33:334-44. [DOI: 10.1016/j.gcb.2009.02.014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
27 Fontanges T, Bailly F, Trepo E, Chevallier M, Maynard-muet M, Nalet B, Beorchia S, Pillon D, Moindrot H, Froissart B, Slaoui M, Tinel X, Pradat P, Trepo C. Discordance between biochemical markers of liver activity and fibrosis (Actitest®–Fibrotest®) and liver biopsy in patients with chronic hepatitis C. Gastroentérologie Clinique et Biologique 2008;32:858-65. [DOI: 10.1016/j.gcb.2008.05.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
28 Ydreborg M, Lisovskaja V, Lagging M, Brehm Christensen P, Langeland N, Buhl MR, Pedersen C, Mørch K, Wejstål R, Norkrans G, Lindh M, Färkkilä M, Westin J. A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis. PLoS One 2014;9:e93601. [PMID: 24699777 DOI: 10.1371/journal.pone.0093601] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Manka P, Zeller A, Syn W. Fibrosis in Chronic Liver Disease: An Update on Diagnostic and Treatment Modalities. Drugs 2019;79:903-27. [DOI: 10.1007/s40265-019-01126-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 9.0] [Reference Citation Analysis]
30 Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y. Fibroindex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007;45:297-306. [DOI: 10.1002/hep.21520] [Cited by in Crossref: 168] [Cited by in F6Publishing: 159] [Article Influence: 12.0] [Reference Citation Analysis]
31 Myers RP. Noninvasive markers of liver fibrosis: playing the probabilities. Liver Int 2008;28:1328-31. [PMID: 19055641 DOI: 10.1111/j.1478-3231.2008.01900.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
32 Rath T, Roderfeld M, Güler C, Wenzel C, Graf J, Beitinger F, Roeb E, Zachoval R. YKL-40 and transient elastography, a powerful team to assess hepatic fibrosis. Scandinavian Journal of Gastroenterology 2011;46:1369-80. [DOI: 10.3109/00365521.2011.613949] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
33 Lejealle C, Castera L. Non-invasive Fibrosis Testing in Patients with Chronic Hepatitis B. Curr Hepatology Rep 2018;17:492-501. [DOI: 10.1007/s11901-018-0439-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Zarski J, David-tchouda S, Trocme C, Margier J, Vilotitch A, Hilleret M, Cagnot C, Boursier V, Ziol M, Sutton A, Layese R, Audureau E, Roudot-thoraval F, Nahon P. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clinics and Research in Hepatology and Gastroenterology 2020;44:524-31. [DOI: 10.1016/j.clinre.2019.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
35 Morra R, Lebray P, Ingiliz P, Ngo Y, Munteanu M, Ratziu V, Poynard T. FibroTest has better diagnostic and prognostic values than the aspartate aminotransferase-to-platelet ratio index in patients with chronic hepatitis C. Hepatology. 2008;47:353-34; author reply 353-34;. [PMID: 18161711 DOI: 10.1002/hep.22046] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
36 Valva P, Ríos DA, De Matteo E, Preciado MV. Chronic hepatitis C virus infection: Serum biomarkers in predicting liver damage. World J Gastroenterol 2016; 22(4): 1367-1381 [PMID: 26819506 DOI: 10.3748/wjg.v22.i4.1367] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
37 Bensamoun SF, Leclerc GE, Debernard L, Cheng X, Robert L, Charleux F, Rhein C, Latrive JP. Cutoff values for alcoholic liver fibrosis using magnetic resonance elastography technique. Alcohol Clin Exp Res. 2013;37:811-817. [PMID: 23216352 DOI: 10.1111/acer.12025] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
38 Ahmed Y, Hussein RS, Basha TA, Khalifa AM, Ibrahim AS, Abdelmoaty AS, Abdella HM, Fahmy AS. Detecting liver fibrosis using a machine learning-based approach to the quantification of the heart-induced deformation in tagged MR images. NMR Biomed. 2020;33:e4215. [PMID: 31730265 DOI: 10.1002/nbm.4215] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
39 Parkes J, Guha IN, Harris S, Rosenberg WM, Roderick PJ. Systematic review of the diagnostic performance of serum markers of liver fibrosis in alcoholic liver disease. Comp Hepatol. 2012;11:5. [PMID: 23273224 DOI: 10.1186/1476-5926-11-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
40 Bosselut N, Taibi L, Guéchot J, Zarski JP, Sturm N, Gelineau MC, Poggi B, Thoret S, Lasnier E, Baudin B. Including osteoprotegerin and collagen IV in a score-based blood test for liver fibrosis increases diagnostic accuracy. Clin Chim Acta. 2013;415:63-68. [PMID: 23022619 DOI: 10.1016/j.cca.2012.09.020] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
41 Dinesen L, Caspary WF, Chapman RW, Dietrich CF, Sarrazin C, Braden B. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Dig Liver Dis. 2008;40:743-748. [PMID: 18339592 DOI: 10.1016/j.dld.2008.01.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
42 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: a systematic review. Hepatology. 2007;46:912-921. [PMID: 17705266 DOI: 10.1002/hep.21835] [Cited by in Crossref: 251] [Cited by in F6Publishing: 239] [Article Influence: 17.9] [Reference Citation Analysis]
43 Liu HB, Zhou JP, Zhang Y, Lv XH, Wang W. Prediction on liver fibrosis using different APRI thresholds when patient age is a categorical marker in patients with chronic hepatitis B. Clin Chim Acta. 2011;412:33-37. [PMID: 20828546 DOI: 10.1016/j.cca.2010.08.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
44 Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, Koziel MJ, Graham C, Tumilty S, Skolnik P, Stuver S, Horsburgh RC, Cotton D. Noninvasive Markers of Liver Fibrosis Are Highly Predictive of Liver-Related Death in a Cohort of HCV-Infected Individuals With and Without HIV Infection. American Journal of Gastroenterology 2010;105:1346-53. [DOI: 10.1038/ajg.2009.746] [Cited by in Crossref: 111] [Cited by in F6Publishing: 99] [Article Influence: 10.1] [Reference Citation Analysis]
45 Alqahtani SA, Schattenberg JM. Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practice. Expert Rev Mol Diagn 2021;:1-14. [PMID: 34346799 DOI: 10.1080/14737159.2021.1964958] [Reference Citation Analysis]
46 Nguyen-Khac E, Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol. 2006;18:1321-1325. [PMID: 17099382 DOI: 10.1097/01.meg.0000243884.55562.37] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
47 Parkes J, Guha IN, Roderick P, Harris S, Cross R, Manos MM, Irving W, Zaitoun A, Wheatley M, Ryder S. Enhanced Liver Fibrosis (ELF) test accurately identifies liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2011;18:23-31. [PMID: 20196799 DOI: 10.1111/j.1365-2893.2009.01263.x] [Cited by in Crossref: 108] [Cited by in F6Publishing: 109] [Article Influence: 10.8] [Reference Citation Analysis]
48 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 11.4] [Reference Citation Analysis]
49 Sturm N, Marlu A, Arvers P, Zarski JP, Leroy V. Comparative assessment of liver fibrosis by computerized morphometry in naïve patients with chronic hepatitis B and C. Liver Int 2013;33:428-38. [PMID: 23402612 DOI: 10.1111/liv.12092] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
50 Paradis V, Bedossa P. In the new area of noninvasive markers of hepatocellular carcinoma. J Hepatol 2007;46:9-11. [PMID: 17112623 DOI: 10.1016/j.jhep.2006.10.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
51 Castera L. Non-invasive assessment of liver fibrosis in chronic hepatitis C. Hepatol Int. 2011;5:625-634. [PMID: 21484142 DOI: 10.1007/s12072-010-9240-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 4.7] [Reference Citation Analysis]
52 Lunel-Fabiani F. Recent advances in hepatitis C virus research and understanding the biology of the virus. World J Gastroenterol 2007; 13(17): 2404-2405 [PMID: 17552022 DOI: 10.3748/wjg.v13.i17.2404] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
53 Shiha G, Sarin SK, Ibrahim AE, Omata M, Kumar A, Lesmana LA, Leung N, Tozun N, Hamid S, Jafri W, Maruyama H, Bedossa P, Pinzani M, Chawla Y, Esmat G, Doss W, Elzanaty T, Sakhuja P, Nasr AM, Omar A, Wai CT, Abdallah A, Salama M, Hamed A, Yousry A, Waked I, Elsahar M, Fateen A, Mogawer S, Hamdy H, Elwakil R, Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C. Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). Hepatol Int. 2009;3:323-333. [PMID: 19669358 DOI: 10.1007/s12072-008-9114-x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 4.9] [Reference Citation Analysis]
54 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality. J Cell Mol Med. 2007;11:1031-1051. [PMID: 17979881 DOI: 10.1111/j.1582-4934.2007.00092.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 5.3] [Reference Citation Analysis]
55 Zhou K, Lu LG. Assessment of fibrosis in chronic liver diseases. Journal of Digestive Diseases 2009;10:7-14. [DOI: 10.1111/j.1751-2980.2008.00356.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 2.9] [Reference Citation Analysis]
56 Burroughs AK, Cholongitas E. Non-invasive tests for liver fibrosis: encouraging or discouraging results? J Hepatol. 2007;46:751-755. [PMID: 17383047 DOI: 10.1016/j.jhep.2007.02.017] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
57 Zou X, Chi X, Pan Y, Du D, Sun H, Matsuda A, Li W, Kuno A, Zhang X, Narimatsu H, Niu J, Zhang Y. LecT-Hepa facilitates estimating treatment outcome during interferon therapy in chronic hepatitis C patients. Clin Proteomics 2014;11:44. [PMID: 25593566 DOI: 10.1186/1559-0275-11-44] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
58 Vallet-pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-venier V, Fontaine H, Pol S. FIB-4: An inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007;46:32-6. [DOI: 10.1002/hep.21669] [Cited by in Crossref: 1026] [Cited by in F6Publishing: 981] [Article Influence: 73.3] [Reference Citation Analysis]
59 Zarski J, Bedossa P, Bronowicki J, Doffoel M, Poynard T. Utilisation des marqueurs non invasifs de fibrose dans la prise en charge de l’hépatite C. Gastroentérologie Clinique et Biologique 2007;31:34-9. [DOI: 10.1016/s0399-8320(07)92561-0] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
60 Calès P, Zarski JP, Marc Chapplain J, Bertrais S, Sturm N, Michelet C, Babany G, Chaigneau J, Eddine Charaf M; multicentric groups (Fibrosys, ANRS HC 12, Fibrostop). Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry: Precise evaluation of fibrosis progression. Journal of Viral Hepatitis 2012;19:e143-53. [DOI: 10.1111/j.1365-2893.2011.01531.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
61 Ratziu V, Martin L, Fedchuk L, Poynard T. Can nonalcoholic steatohepatitis be diagnosed without liver biopsy? Biomark Med 2009;3:353-61. [PMID: 20477484 DOI: 10.2217/bmm.09.36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
62 Vergara M, Bejarano G, Dalmau B, Gil M, Miquel M, Sanchez-Delgado J, Casas M, Puig J, Martinez-Bauer E, Dosal A, Lopez M, Moreno L, Valero O, Bella MR, Calvet X. Usefulness of indirect noninvasive methods in predicting progression to cirrhosis in chronic hepatitis C. Eur J Gastroenterol Hepatol 2015;27:826-33. [PMID: 26043289 DOI: 10.1097/MEG.0000000000000346] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
63 Patel K, Sebastiani G. Limitations of non-invasive tests for assessment of liver fibrosis. JHEP Rep. 2020;2:100067. [PMID: 32118201 DOI: 10.1016/j.jhepr.2020.100067] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 47.0] [Reference Citation Analysis]
64 Cheung KJ, Tilleman K, Deforce D, Colle I, Moreno C, Gustot T, Van Vlierberghe H. Usefulness of a novel serum proteome-derived index FI-PRO (fibrosis-protein) in the prediction of fibrosis in chronic hepatitis C. Eur J Gastroenterol Hepatol. 2011;23:701-710. [PMID: 21623191 DOI: 10.1097/meg.0b013e3283471b74] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
65 Boursier J, Rousselet M, Aubé C, Calès P. Liver fibrosis in patients with non-alcoholic fatty liver disease: diagnostic options in clinical practice. Expert Opinion on Medical Diagnostics 2012;6:381-94. [DOI: 10.1517/17530059.2012.691878] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
66 Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18(39): 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
67 Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology. 2011;53:325-335. [PMID: 21254180 DOI: 10.1002/hep.24013] [Cited by in Crossref: 272] [Cited by in F6Publishing: 248] [Article Influence: 24.7] [Reference Citation Analysis]
68 Labarca G, Horta G. Obstructive sleep apnea and nonalcoholic fatty liver disease: do we need to consider this association in current clinical practice? Sleep Med 2021;77:355-6. [PMID: 32564917 DOI: 10.1016/j.sleep.2020.05.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 朱霞, 唐红. 瞬时弹性扫描仪在肝纤维化诊断中的应用价值. 世界华人消化杂志 2010; 18(9): 906-912 [DOI: 10.11569/wcjd.v18.i9.906] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
70 Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and treatment of hepatic fibrosis (2019). J Dig Dis 2020;21:127-38. [PMID: 32108989 DOI: 10.1111/1751-2980.12854] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Jarcuska P, Janicko M, Veselíny E, Jarcuska P, Skladaný L. Circulating markers of liver fibrosis progression. Clin Chim Acta. 2010;411:1009-1017. [PMID: 20399764 DOI: 10.1016/j.cca.2010.04.009] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 5.1] [Reference Citation Analysis]
72 Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta. 2007;381:107-113. [PMID: 17399697 DOI: 10.1016/j.cca.2007.02.038] [Cited by in Crossref: 132] [Cited by in F6Publishing: 120] [Article Influence: 9.4] [Reference Citation Analysis]
73 Hernández-Bartolomé A, López-Rodríguez R, Rodríguez-Muñoz Y, Martín-Vílchez S, Borque MJ, García-Buey L, González-Moreno L, Real Y, Moreno-Otero R, Sanz-Cameno P. Angiopoietin-2 Serum Levels Improve Noninvasive Fibrosis Staging in Chronic Hepatitis C: A Fibrogenic-Angiogenic Link. PLoS One 2013;8:e66143. [PMID: 23823085 DOI: 10.1371/journal.pone.0066143] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
74 Abbas SH, Pickett E, Lomas DA, Thorburn D, Gooptu B, Hurst JR, Marshall A. Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. BMJ Open Respir Res 2020;7:e000820. [PMID: 33323365 DOI: 10.1136/bmjresp-2020-000820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Takaki S, Kawakami Y, Miyaki D, Nakahara T, Naeshiro N, Murakami E, Tanaka M, Honda Y, Yokoyama S, Nagaoki Y. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients. Hepatol Res. 2014;44:280-287. [PMID: 23607728 DOI: 10.1111/hepr.12129] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
76 Wallace K, Burt AD, Wright MC. Liver fibrosis. Biochem J. 2008;411:1-18. [PMID: 18333835 DOI: 10.1042/bj20071570] [Cited by in Crossref: 217] [Cited by in F6Publishing: 110] [Article Influence: 16.7] [Reference Citation Analysis]
77 Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T, Moriwaki EI, Shimomura S, Iijima H, Nakamura H, Nishiguchi S. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol 2012; 4(1): 11-17 [PMID: 22312451 DOI: 10.4254/wjh.v4.i1.11] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
78 Verlinden W, Bourgeois S, Gigase P, Thienpont C, Vonghia L, Vanwolleghem T, Michielsen P, Francque S. Liver Fibrosis Evaluation Using Real-time Shear Wave Elastography in Hepatitis C-Monoinfected and Human Immunodeficiency Virus/Hepatitis C-Coinfected Patients. J Ultrasound Med 2016;35:1299-308. [PMID: 27151906 DOI: 10.7863/ultra.15.08066] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
79 Cadranel J, Castera L, Cales P. La ponction biopsie du foie dans le diagnostic et la prise en charge des maladies chroniques du foie. Gastroentérologie Clinique et Biologique 2006;30:121-3. [DOI: 10.1016/s0399-8320(06)73126-8] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
80 Attallah AM, El-Far M, Omran MM, Farid K, Albannan MS, El-Dosoky I. Noninvasive diagnosis of liver fibrosis and cirrhosis in chronic hepatitis C patients. J Clin Lab Anal 2013;27:121-9. [PMID: 23460258 DOI: 10.1002/jcla.21572] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
81 Calès P, Boursier J, Chaigneau J, Oberti F, Rousselet M. Treatment of liver fibrosis: Clinical aspects. Gastroentérologie Clinique et Biologique 2009;33:958-66. [DOI: 10.1016/j.gcb.2009.07.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
82 Gómez-Domínguez E, Mendoza J, Rubio S, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. Transient elastography: a valid alternative to biopsy in patients with chronic liver disease. Aliment Pharmacol Ther 2006;24:513-8. [PMID: 16886917 DOI: 10.1111/j.1365-2036.2006.02999.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 77] [Article Influence: 6.1] [Reference Citation Analysis]
83 Pang JX, Zimmer S, Niu S, Crotty P, Tracey J, Pradhan F, Shaheen AA, Coffin CS, Heitman SJ, Kaplan GG, Swain MG, Myers RP. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. PLoS One 2014;9:e95776. [PMID: 24755824 DOI: 10.1371/journal.pone.0095776] [Cited by in Crossref: 68] [Cited by in F6Publishing: 63] [Article Influence: 9.7] [Reference Citation Analysis]
84 Miyata M, Kuroda M, Unakami M, Tasaki K, Migita K, Ohira H. Validation of the fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Modern Rheumatology 2019;29:936-42. [DOI: 10.1080/14397595.2018.1542962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
85 Soresi M, Giannitrapani L, Cervello M, Licata A, Montalto G. Non invasive tools for the diagnosis of liver cirrhosis. World J Gastroenterol 2014; 20(48): 18131-18150 [PMID: 25561782 DOI: 10.3748/wjg.v20.i48.18131] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.9] [Reference Citation Analysis]
86 Nelson DR, Davis GL, Jacobson I, Everson GT, Fried MW, Harrison SA, Hassanein T, Jensen DM, Lindsay KL, Terrault N, Zein N. Hepatitis C virus: a critical appraisal of approaches to therapy. Clin Gastroenterol Hepatol 2009;7:397-414; quiz 366. [PMID: 19114127 DOI: 10.1016/j.cgh.2008.11.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
87 Lei B, Liu Y, Dong C, Chen X, Zhang X, Diao X, Yang G, Liu J, Yao S, Li H, Yuan J, Li S, Le X, Lin Y, Zeng W. Assessment of liver fibrosis in chronic hepatitis B via multimodal data. Neurocomputing 2017;253:169-76. [DOI: 10.1016/j.neucom.2016.09.128] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
88 Avila MA, Dufour JF, Gerbes AL, Zoulim F, Bataller R, Burra P, Cortez-Pinto H, Gao B, Gilmore I, Mathurin P, Moreno C, Poznyak V, Schnabl B, Szabo G, Thiele M, Thursz MR. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut 2020;69:764-80. [PMID: 31879281 DOI: 10.1136/gutjnl-2019-319720] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 10.5] [Reference Citation Analysis]
89 Lubner MG, Pickhardt PJ. Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis. Gastroenterol Clin North Am 2018;47:569-84. [PMID: 30115438 DOI: 10.1016/j.gtc.2018.04.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
90 Sanal MG. Biomarkers in nonalcoholic fatty liver disease-the emperor has no clothes? World J Gastroenterol 2015; 21(11): 3223-3231 [PMID: 25805928 DOI: 10.3748/wjg.v21.i11.3223] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
91 Matta B, Lee TH, Patel K. Use of Non-invasive Testing to Stage Liver Fibrosis in Patients with HIV. Curr HIV/AIDS Rep 2016;13:279-88. [PMID: 27485838 DOI: 10.1007/s11904-016-0329-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
92 Martel-Laferrière V, Wong M, Dieterich DT. HIV/hepatitis C virus-coinfected patients and cirrhosis: how to diagnose it and what to do next? Clin Infect Dis 2014;58:840-7. [PMID: 24178247 DOI: 10.1093/cid/cit714] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
93 Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Rafiq N, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1224-1229, 1229.e1-1229. e2. [PMID: 19559819 DOI: 10.1016/j.cgh.2009.06.007] [Cited by in Crossref: 170] [Cited by in F6Publishing: 160] [Article Influence: 14.2] [Reference Citation Analysis]
94 Tsochatzis EA, Castera L. Assessing liver disease in HIV–HCV coinfected patients: . Current Opinion in HIV and AIDS 2015;10:316-22. [DOI: 10.1097/coh.0000000000000176] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
95 Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D. Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med. 2006;260:142-150. [PMID: 16882278 DOI: 10.1111/j.1365-2796.2006.01673.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
96 Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, Xu HT, Mao YM, Zeng MD, Lu LG. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol. 2010;25:1569-1577. [PMID: 20796157 DOI: 10.1111/j.1440-1746.2010.06383.x] [Cited by in Crossref: 71] [Cited by in F6Publishing: 69] [Article Influence: 6.5] [Reference Citation Analysis]
97 Lombardi R, Buzzetti E, Roccarina D, Tsochatzis EA. Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease. World J Gastroenterol 2015; 21(39): 11044-11052 [PMID: 26494961 DOI: 10.3748/wjg.v21.i39.11044] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
98 Castera L. Invasive and non-invasive methods for the assessment of fibrosis and disease progression in chronic liver disease. Best Pract Res Clin Gastroenterol. 2011;25:291-303. [PMID: 21497746 DOI: 10.1016/j.bpg.2011.02.003] [Cited by in Crossref: 91] [Cited by in F6Publishing: 79] [Article Influence: 9.1] [Reference Citation Analysis]
99 Arrayhani M, Sqalli T, Tazi N, El Youbi R, Chaouch S, Aqodad N, Ibrahimi SA. Non invasive assessment of liver fibrosis in chronic hemodialysis patients with viral hepatitis C. Pan Afr Med J 2015;22:273. [PMID: 26958136 DOI: 10.11604/pamj.2015.22.273.2311] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
100 Cholongitas E, Burroughs AK, Dhillon AP. Liver Biopsy. In: Mcdonald JW, Burroughs AK, Feagan BG, Fennerty MB, editors. Evidence‐Based Gastroenterology and Hepatology. Wiley; 2010. pp. 762-70. [DOI: 10.1002/9781444314403.ch46] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Seto WK, Lee CF, Lai CL, Ip PP, Fong DY, Fung J, Wong DK, Yuen MF. A new model using routinely available clinical parameters to predict significant liver fibrosis in chronic hepatitis B. PLoS One. 2011;6:e23077. [PMID: 21853071 DOI: 10.1371/journal.pone.0023077] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
102 Zhang GM, Xia YJ. Reference Intervals of Fibrosis Index Based on Four Indicators in Healthy Elderly Chinese. J Clin Lab Anal 2016;30:645-8. [PMID: 26953257 DOI: 10.1002/jcla.21916] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
103 Smith JO, Sterling RK. Systematic review: non-invasive methods of fibrosis analysis in chronic hepatitis C. Alimentary Pharmacology & Therapeutics 2009;30:557-76. [DOI: 10.1111/j.1365-2036.2009.04062.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 7.2] [Reference Citation Analysis]
104 Guéchot J. Non-invasive evaluation of liver fibrosis: More well-validated tests available for patient management. Liver Int 2015;35:1643-5. [DOI: 10.1111/liv.12790] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
105 Başar O, Yimaz B, Ekiz F, Giniş Z, Altinbaş A, Aktaş B, Tuna Y, Çoban S, Delibaş N, Yüksel O. Non-invasive tests in prediction of liver fibrosis in chronic hepatitis B and comparison with post-antiviral treatment results. Clin Res Hepatol Gastroenterol 2013;37:152-8. [PMID: 23391746 DOI: 10.1016/j.clinre.2012.07.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
106 Hann HW, Wan S, Lai Y, Hann RS, Myers RE, Patel F, Zhang K, Ye Z, Wang C, Yang H. Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2015;30:131-8. [PMID: 24995497 DOI: 10.1111/jgh.12664] [Cited by in Crossref: 19] [Cited by in F6Publishing: 23] [Article Influence: 3.2] [Reference Citation Analysis]
107 Hermeziu B, Messous D, Fabre M, Munteanu M, Baussan C, Bernard O, Poynard T, Jacquemin E. Evaluation of FibroTest-ActiTest in children with chronic hepatitis C virus infection. Gastroenterol Clin Biol. 2010;34:16-22. [PMID: 19726147 DOI: 10.1016/j.gcb.2009.06.007] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
108 Calès P, Boursier J, Oberti F, Gallois Y, Rousselet MC, Moal V, Macchi L, Chevailler A, Lunel F. [FibroMeters: a family of blood tests for liver fibrosis with high diagnostic performance and applicability in clinical practice]. Pathol Biol (Paris) 2009;57:459-62. [PMID: 19054629 DOI: 10.1016/j.patbio.2008.09.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
109 de Lédinghen V, Poynard T, Wartelle C, Rosenthal E. [Non-invasive evaluation of liver fibrosis in hepatitis C]. Gastroenterol Clin Biol 2008;32:S90-5. [PMID: 18675186 DOI: 10.1016/S0399-8320(08)73271-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
110 Munteanu M, Imbert-Bismut F, Messous D, Morra R, Thabut D, Lebray P, Benhamou Y, Ratziu V, Poynard T. Reproducibility of non-invasive fibrosis biomarkers, FibroMeter and FibroTest, could be improved by respecting the analytical standardizations. Clin Biochem 2008;41:1113-4. [PMID: 18486610 DOI: 10.1016/j.clinbiochem.2008.04.020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
111 Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology. 2012;142:1293-1302.e4. [PMID: 22537436 DOI: 10.1053/j.gastro.2012.02.017] [Cited by in Crossref: 411] [Cited by in F6Publishing: 366] [Article Influence: 45.7] [Reference Citation Analysis]
112 Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH. Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7:696-701. [PMID: 19514117 DOI: 10.1016/j.cgh.2009.01.010] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 3.9] [Reference Citation Analysis]
113 Mbaye PS, Sarr A, Sire JM, Evra ML, Ba A, Daveiga J, Diallo A, Fall F, Chartier L, Simon F, Vray M. Liver stiffness measurement and biochemical markers in Senegalese chronic hepatitis B patients with normal ALT and high viral load. PLoS One 2011;6:e22291. [PMID: 21799814 DOI: 10.1371/journal.pone.0022291] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
114 Bonder A, Tapper EB, Afdhal NH. Contemporary Assessment of Hepatic Fibrosis. Clinics in Liver Disease 2015;19:123-34. [DOI: 10.1016/j.cld.2014.09.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
115 Mondésert B, Marcotte F, Mongeon F, Dore A, Mercier L, Ibrahim R, Asgar A, Miro J, Poirier N, Khairy P. Fontan Circulation: Success or Failure? Canadian Journal of Cardiology 2013;29:811-20. [DOI: 10.1016/j.cjca.2012.12.009] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 5.8] [Reference Citation Analysis]
116 Zvibel I, Halfon P, Fishman S, Penaranda G, Leshno M, Or AB, Halpern Z, Oren R. Syndecan 1 (CD138) serum levels: a novel biomarker in predicting liver fibrosis stage in patients with hepatitis C. Liver Int 2009;29:208-12. [PMID: 18694404 DOI: 10.1111/j.1478-3231.2008.01830.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
117 Ratziu V. Serum fibrosis markers: Death by validation or a leap of faith? Journal of Hepatology 2010;53:222-4. [DOI: 10.1016/j.jhep.2010.04.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
118 Leroy V, Sturm N, Faure P, Trocme C, Marlu A, Hilleret MN, Morel F, Zarski JP. Prospective evaluation of FibroTest®, FibroMeter®, and HepaScore® for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61:28-34. [PMID: 24631902 DOI: 10.1016/j.jhep.2014.02.029] [Cited by in Crossref: 51] [Cited by in F6Publishing: 37] [Article Influence: 7.3] [Reference Citation Analysis]
119 Soussan P, Pol J, Garreau F, Schneider V, Le Pendeven C, Nalpas B, Lacombe K, Bonnard P, Pol S, Kremsdorf D. Expression of defective hepatitis B virus particles derived from singly spliced RNA is related to liver disease. J Infect Dis. 2008;198:218-225. [PMID: 18532883 DOI: 10.1086/589623] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 2.8] [Reference Citation Analysis]
120 Day JW, Rosenberg WM. The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis. Br J Hosp Med 2018;79:694-9. [DOI: 10.12968/hmed.2018.79.12.694] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
121 Belinsky GS, Parke AL, Huang Q, Blanchard K, Jayadev S, Stoll R, Rothe M, Achenie LEK, Gupta RR, Wu GY, Rosenberg DW. The Contribution of Methotrexate Exposure and Host Factors on Transcriptional Variance in Human Liver. Toxicological Sciences 2007;97:582-94. [DOI: 10.1093/toxsci/kfm067] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
122 Day J, Patel P, Parkes J, Rosenberg W. Derivation and Performance of Standardized Enhanced Liver Fibrosis (ELF) Test Thresholds for the Detection and Prognosis of Liver Fibrosis. J Appl Lab Med. 2019;3:815-826. [PMID: 31639756 DOI: 10.1373/jalm.2018.027359] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
123 Corpechot C. Utility of Noninvasive Markers of Fibrosis in Cholestatic Liver Diseases. Clin Liver Dis 2016;20:143-58. [PMID: 26593296 DOI: 10.1016/j.cld.2015.08.013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
124 Trabut JB, Thépot V, Terris B, Sogni P, Nalpas B, Pol S. [Prognosis assessment of alcoholic liver disease: how and why?]. Presse Med 2014;43:124-34. [PMID: 24140195 DOI: 10.1016/j.lpm.2013.04.016] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
125 Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Rev Gastroenterol Hepatol 2008;5:95-106. [DOI: 10.1038/ncpgasthep1025] [Cited by in Crossref: 123] [Cited by in F6Publishing: 121] [Article Influence: 9.5] [Reference Citation Analysis]
126 Aizawa N, Enomoto H, Imanishi H, Saito M, Iwata Y, Tanaka H, Ikeda N, Sakai Y, Takashima T, Iwai T. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol. 2012;4:11-17. [PMID: 22312451 DOI: 10.5754/hge12064] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
127 Attallah AM, Omran MM, Farid K, El-Bendary M, Emran TM, Albannan MS, El-Dosoky I. Development of a novel score for liver fibrosis staging and comparison with eight simple laboratory scores in large numbers of HCV-monoinfected patients. Clin Chim Acta. 2012;413:1725-1730. [PMID: 22759976 DOI: 10.1016/j.cca.2012.06.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
128 Poynard T, Ngo Y, Marcellin P, Hadziyannis S, Ratziu V, Benhamou Y. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat. 2009;16:203-213. [PMID: 19175871 DOI: 10.1111/j.1365-2893.2008.01065.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
129 Tural C, Tor J, Sanvisens A, Pérez-Alvarez N, Martínez E, Ojanguren I, García-Samaniego J, Rockstroh J, Barluenga E, Muga R, Planas R, Sirera G, Rey-Joly C, Clotet B. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroenterol Hepatol 2009;7:339-45. [PMID: 19171202 DOI: 10.1016/j.cgh.2008.11.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
130 Sebastiani G, Gkouvatsos K, Plebani M. Non-invasive assessment of liver fibrosis: it is time for laboratory medicine. Clin Chem Lab Med. 2011;49:13-32. [PMID: 20961196 DOI: 10.1515/cclm.2011.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
131 Van Leeuwen DJ, Balabaud C, Crawford JM, Bioulac–sage P, Dhillon AP. A Clinical and Histopathologic Perspective on Evolving Noninvasive and Invasive Alternatives for Liver Biopsy. Clinical Gastroenterology and Hepatology 2008;6:491-6. [DOI: 10.1016/j.cgh.2008.02.023] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
132 Cross T, Antoniades C, Harrison P. Non-invasive markers for the prediction of fibrosis in chronic hepatitis C infection. Hepatol Res 2008;38:762-9. [PMID: 18462378 DOI: 10.1111/j.1872-034X.2008.00364.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
133 Parsian H, Alizadeh M, Negahdar H. Would the physicians eventually obsolete the liver biopsy for the assessment of liver fibrosis? Hepat Mon 2012;12:353-4. [PMID: 22783349 DOI: 10.5812/hepatmon.6227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
134 Cacoub P, Carrat F, Bédossa P, Lambert J, Pénaranda G, Perronne C, Pol S, Halfon P. Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients: The fibrovic study – ANRS HC02. Journal of Hepatology 2008;48:765-73. [DOI: 10.1016/j.jhep.2008.01.025] [Cited by in Crossref: 70] [Cited by in F6Publishing: 55] [Article Influence: 5.4] [Reference Citation Analysis]
135 Abd Alla MDA, Dawood RM, Rashed HAE, Farrag G, Ammar IAE, Mahmoud MMA, Salum GM, Altanbouly AMA, El Meguid MA, Awady MKE. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Arch Virol 2021;166:1071-81. [PMID: 33533976 DOI: 10.1007/s00705-021-04969-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Jaroszewicz J, Flisiak-jackiewicz M, Lebensztejn D, Flisiak R. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis. Expert Opinion on Investigational Drugs 2015;24:1229-39. [DOI: 10.1517/13543784.2015.1057568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
137 Selph SS, Ginsburg AD, Chou R. Impact of contacting study authors to obtain additional data for systematic reviews: diagnostic accuracy studies for hepatic fibrosis. Syst Rev 2014;3:107. [PMID: 25239493 DOI: 10.1186/2046-4053-3-107] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
138 Saludes V, González V, Planas R, Matas L, Ausina V, Martró E. Tools for the diagnosis of hepatitis C virus infection and hepatic fibrosis staging. World J Gastroenterol 2014; 20(13): 3431-3442 [PMID: 24707126 DOI: 10.3748/wjg.v20.i13.3431] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
139 Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, Hige S, Sakamoto M, Kage M, Mizokami M, Narimatsu H. A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep. 2013;3:1065. [PMID: 23323209 DOI: 10.1038/srep01065] [Cited by in Crossref: 215] [Cited by in F6Publishing: 197] [Article Influence: 26.9] [Reference Citation Analysis]
140 Albhaisi S, Sanyal AJ. Applying Non-Invasive Fibrosis Measurements in NAFLD/NASH: Progress to Date. Pharmaceut Med 2019;33:451-63. [PMID: 31933238 DOI: 10.1007/s40290-019-00305-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
141 Guillaud O, Dumortier J, Traclet J, Restier L, Joly P, Chapuis-Cellier C, Lachaux A, Mornex JF. Assessment of liver fibrosis by transient elastography (Fibroscan®) in patients with A1AT deficiency. Clin Res Hepatol Gastroenterol 2019;43:77-81. [PMID: 30612958 DOI: 10.1016/j.clinre.2018.08.016] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 5.5] [Reference Citation Analysis]
142 Vignier N, Esmat G, Elsharkawy A, Hassany M, Bonnard P, Delarocque-Astagneau E, Said M, Raafat R, El-Hoseiny M, Fontanet A, Mohamed MK, Vray M. Reproducibility of liver stiffness measurements in hepatitis C virus (HCV)-infected patients in Egypt. J Viral Hepat 2011;18:e358-65. [PMID: 21692948 DOI: 10.1111/j.1365-2893.2010.01433.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
143 Enomoto H, Aizawa N, Nakamura H, Sakai Y, Iwata Y, Tanaka H, Ikeda N, Aoki T, Yuri Y, Yoh K. An Increased Ratio of Glycated Albumin to HbA1c Is Associated with the Degree of Liver Fibrosis in Hepatitis B Virus-Positive Patients. Gastroenterol Res Pract. 2014;2014:351396. [PMID: 24693282 DOI: 10.1155/2014/351396] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
144 Mueller S, Seitz HK, Rausch V. Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol 2014; 20(40): 14626-14641 [PMID: 25356026 DOI: 10.3748/wjg.v20.i40.14626] [Cited by in CrossRef: 73] [Cited by in F6Publishing: 51] [Article Influence: 10.4] [Reference Citation Analysis]
145 Boursier J, Konate A, Guilluy M, Gorea G, Sawadogo A, Quemener E, Oberti F, Reaud S, Hubert-Fouchard I, Dib N. Learning curve and interobserver reproducibility evaluation of liver stiffness measurement by transient elastography. Eur J Gastroenterol Hepatol. 2008;20:693-701. [PMID: 18679074 DOI: 10.1097/meg.0b013e3282f51992] [Cited by in Crossref: 75] [Cited by in F6Publishing: 12] [Article Influence: 6.3] [Reference Citation Analysis]
146 Calès P, Boursier J, Oberti F, Moal V, Fouchard Hubert I, Bertrais S, Hunault G, Rousselet MC; multicentric groups (SNIFF, ANRS HC 23). A single blood test adjusted for different liver fibrosis targets improves fibrosis staging and especially cirrhosis diagnosis. Hepatol Commun 2018;2:455-66. [PMID: 29619423 DOI: 10.1002/hep4.1161] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
147 Armutcu F, Akyol S, Ucar F, Erdogan S, Akyol O. Markers in Nonalcoholic Steatohepatitis. Elsevier; 2013. pp. 67-125. [DOI: 10.1016/b978-0-12-407680-8.00004-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
148 Halfon P, Munteanu M, Poynard T. FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol. 2008;32:22-39. [PMID: 18973844 DOI: 10.1016/s0399-8320(08)73991-5] [Cited by in Crossref: 77] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
149 Nguyen-khac E. Résultats et place du Fibroscan® dans le diagnostic non invasif de la fibrose hépatique. La Revue de Médecine Interne 2007;28:94-102. [DOI: 10.1016/j.revmed.2006.10.329] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
150 Trivedi HD, Patwardhan VR, Malik R. Chronic hepatitis C infection — Noninvasive assessment of liver fibrosis in the era of direct acting antivirals. Digestive and Liver Disease 2019;51:183-9. [DOI: 10.1016/j.dld.2018.11.016] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
151 Schiavon LL, Narciso-Schiavon JL, Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20(11): 2854-2866 [PMID: 24659877 DOI: 10.3748/wjg.v20.i11.2854] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 44] [Article Influence: 6.7] [Reference Citation Analysis]
152 Zeng DW, Liu YR, Zhang JM, Zhu YY, Lin S, You J, Li YB, Chen J, Zheng Q, Jiang JJ, Dong J. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease. PLoS One. 2013;8:e77942. [PMID: 24282481 DOI: 10.1371/journal.pone.0077942] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
153 Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20(32): 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033] [Cited by in CrossRef: 117] [Cited by in F6Publishing: 96] [Article Influence: 16.7] [Reference Citation Analysis]
154 Calès P, Halfon P, Batisse D, Carrat F, Perré P, Penaranda G, Guyader D, d’Alteroche L, Fouchard-Hubert I, Michelet C. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol. 2010;53:238-244. [PMID: 20493576 DOI: 10.1016/j.jhep.2010.03.007] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.0] [Reference Citation Analysis]
155 Kennedy P, Wagner M, Castéra L, Hong CW, Johnson CL, Sirlin CB, Taouli B. Quantitative Elastography Methods in Liver Disease: Current Evidence and Future Directions. Radiology 2018;286:738-63. [PMID: 29461949 DOI: 10.1148/radiol.2018170601] [Cited by in Crossref: 119] [Cited by in F6Publishing: 103] [Article Influence: 39.7] [Reference Citation Analysis]
156 Coulbault L, Ritz L, Vabret F, Lannuzel C, Boudehent C, Nowoczyn M, Beaunieux H, Pitel AL. Thiamine and phosphate esters concentrations in whole blood and serum of patients with alcohol use disorder: a relation with cognitive deficits. Nutr Neurosci 2021;24:530-41. [PMID: 31419185 DOI: 10.1080/1028415X.2019.1652438] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Calès P, Boursier J, Oberti F, Hubert I, Gallois Y, Rousselet MC, Dib N, Moal V, Macchi L, Chevailler A. FibroMeters: a family of blood tests for liver fibrosis. Gastroenterol Clin Biol. 2008;32:40-51. [PMID: 18973845 DOI: 10.1016/s0399-8320(08)73992-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
158 Kim M, Lee Y, Yoon JS, Lee M, Kye SS, Kim SW, Cho Y. The FIB-4 Index Is a Useful Predictor for the Development of Hepatocellular Carcinoma in Patients with Coexisting Nonalcoholic Fatty Liver Disease and Chronic Hepatitis B. Cancers (Basel) 2021;13:2301. [PMID: 34064988 DOI: 10.3390/cancers13102301] [Reference Citation Analysis]
159 Bourlière M, Pénaranda G, Adhoute X, Oules V, Castellani P. Combining non-invasive methods for assessment of liver fibrosis. Gastroentérologie Clinique et Biologique 2008;32:73-9. [DOI: 10.1016/s0399-8320(08)73996-4] [Cited by in Crossref: 9] [Article Influence: 0.7] [Reference Citation Analysis]
160 Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:775-782. [PMID: 17321634 DOI: 10.1016/j.jhep.2006.12.013] [Cited by in Crossref: 164] [Cited by in F6Publishing: 148] [Article Influence: 11.7] [Reference Citation Analysis]
161 Leung JC, Loong TC, Pang J, Wei JL, Wong VW. Invasive and non-invasive assessment of portal hypertension. Hepatol Int 2018;12:44-55. [PMID: 28361299 DOI: 10.1007/s12072-017-9795-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
162 Morikawa H, Kawada N. Non-invasive diagnosis of liver fibrosis. Clin J Gastroenterol 2011;4:283-91. [DOI: 10.1007/s12328-011-0248-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
163 Gharibvand MM, Asare M, Motamedfar A, Alavinejad P, Momeni M. Ultrasound shear wave elastography and liver biopsy to determine liver fibrosis in adult patients. J Family Med Prim Care 2020;9:943-9. [PMID: 32318450 DOI: 10.4103/jfmpc.jfmpc_828_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
164 Sebastiani G, Alberti A. How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? J Viral Hepat. 2012;19 Suppl 1:18-32. [PMID: 22233410 DOI: 10.1111/j.1365-2893.2011.01518.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.2] [Reference Citation Analysis]
165 Ducancelle A, Leroy V, Vergniol J, Sturm N, Le Bail B, Zarski JP, Nguyen Khac E, Salmon D, de Ledinghen V, Calès P. A Single Test Combining Blood Markers and Elastography is More Accurate Than Other Fibrosis Tests in the Main Causes of Chronic Liver Diseases. Journal of Clinical Gastroenterology 2017;51:639-49. [DOI: 10.1097/mcg.0000000000000788] [Cited by in Crossref: 17] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
166 Buffet C. [Noninvasive markers of fibrosis: replacement for liver biopsy?]. Presse Med 2007;36:453-5. [PMID: 17336854 DOI: 10.1016/j.lpm.2006.12.011] [Reference Citation Analysis]
167 Aita JS, Harrison SA. Liver biopsy versus noninvasive testing in chronic hepatitis C: Where do we stand in 2008? Curr hepatitis rep 2008;7:51-9. [DOI: 10.1007/s11901-008-0008-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
168 Boursier J, Dib N, Oberti F, Calès P. Caractéristiques et interprétation des tests sanguins de fibrose hépatique. Gastroentérologie Clinique et Biologique 2007;31:511-23. [DOI: 10.1016/s0399-8320(07)89421-8] [Cited by in Crossref: 5] [Article Influence: 0.4] [Reference Citation Analysis]
169 Bourlière M, Kahloun A, Gascou-Tessonnier G. Analogs and fibrosis regression in hepatitis B. Gastroenterol Clin Biol 2009;33:923-9. [PMID: 19640665 DOI: 10.1016/j.gcb.2009.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
170 Ho AS, Cheng CC, Lee SC, Liu ML, Lee JY, Wang WM, Wang CC. Novel biomarkers predict liver fibrosis in hepatitis C patients: alpha 2 macroglobulin, vitamin D binding protein and apolipoprotein AI. J Biomed Sci 2010;17:58. [PMID: 20630109 DOI: 10.1186/1423-0127-17-58] [Cited by in Crossref: 58] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
171 Sosner P, Wangermez M, Chagneau-Derrode C, Le Moal G, Silvain C. Atherosclerosis risk in HIV-infected patients: the influence of hepatitis C virus co-infection. Atherosclerosis. 2012;222:274-277. [PMID: 22417840 DOI: 10.1016/j.atherosclerosis.2012.02.027] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
172 Pockros PJ. Noninvasive Markers of Fibrosis in Chronic Hepatitis Patients: . Journal of Clinical Gastroenterology 2006;40:461-3. [DOI: 10.1097/00004836-200607000-00001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
173 Halfon P, Bourlière M, Pénaranda G, Cacoub P. [Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection]. Rev Med Interne 2006;27:751-61. [PMID: 16815598 DOI: 10.1016/j.revmed.2006.03.037] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
174 Patel K, Nelson DR, Rockey DC, Afdhal NH, Smith KM, Oh E, Hettinger K, Vallée M, Dev A, Smith-Riggs M. Correlation of FIBROSpect II with histologic and morphometric evaluation of liver fibrosis in chronic hepatitis C. Clin Gastroenterol Hepatol. 2008;6:242-247. [PMID: 18187364 DOI: 10.1016/j.cgh.2007.11.009] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
175 Lunel-Fabiani F, Mansour W, Amar AO, Aye M, Le Gal F, Malick FZ, Baïdy L, Brichler S, Veillon P, Ducancelle A, Gordien E, Rosenheim M. Impact of hepatitis B and delta virus co-infection on liver disease in Mauritania: a cross sectional study. J Infect 2013;67:448-57. [PMID: 23796871 DOI: 10.1016/j.jinf.2013.06.008] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
176 Qu Y, Gao C, Zhou K, Zhao Y, Xu M, Lu L. Serum N-glycomic markers in combination with panels improves the diagnosis of chronic hepatitis B. Annals of Hepatology 2012;11:202-12. [DOI: 10.1016/s1665-2681(19)31025-7] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
177 Benlloch S, Heredia L, Barquero C, Rayón J, Pina R, Aguilera V, Prieto M, Berenguer M. Prospective validation of a noninvasive index for predicting liver fibrosis in hepatitis C virus-infected liver transplant recipients: Liver Transplantation HCV Fibrosis Index. Liver Transpl 2009;15:1798-807. [DOI: 10.1002/lt.21919] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
178 Kim MY, Jeong WK, Baik SK. Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol 2014; 20(15): 4300-4315 [PMID: 24764667 DOI: 10.3748/wjg.v20.i15.4300] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 58] [Article Influence: 9.3] [Reference Citation Analysis]
179 Chin JL, Pavlides M, Moolla A, Ryan JD. Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol. 2016;7:159. [PMID: 27378924 DOI: 10.3389/fphar.2016.00159] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
180 Bracht T, Mölleken C, Ahrens M, Poschmann G, Schlosser A, Eisenacher M, Stühler K, Meyer HE, Schmiegel WH, Holmskov U, Sorensen GL, Sitek B. Evaluation of the biomarker candidate MFAP4 for non-invasive assessment of hepatic fibrosis in hepatitis C patients. J Transl Med 2016;14:201. [PMID: 27378383 DOI: 10.1186/s12967-016-0952-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
181 Nguyen-khac E, Saint-leger P, Tramier B, Coevoet H, Capron D, Dupas J. Noninvasive Diagnosis of Large Esophageal Varices by Fibroscan: Strong Influence of the Cirrhosis Etiology: FIBROSCAN FOR LARGE VARICES PREDICTION. Alcoholism: Clinical and Experimental Research 2010. [DOI: 10.1111/j.1530-0277.2010.01191.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 25] [Article Influence: 1.4] [Reference Citation Analysis]
182 Munteanu M, Ratziu V, Poynard T. The Risk of Multiplying Diagnostic Combinations in the Absence of a Perfect Gold Standard For a Fibrosis Test. American Journal of Gastroenterology 2011;106:1853. [DOI: 10.1038/ajg.2011.259] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
183 Cheah MC, McCullough AJ, Goh GB. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease. J Clin Transl Hepatol. 2017;5:261-271. [PMID: 28936407 DOI: 10.14218/jcth.2017.00009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
184 Frulio N, Trillaud H. Ultrasound elastography in liver. Diagn Interv Imaging. 2013;94:515-534. [PMID: 23623211 DOI: 10.1016/j.diii.2013.02.005] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 13.8] [Reference Citation Analysis]
185 Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol. 2007;7:40. [PMID: 17937811 DOI: 10.1186/1471-230x-7-40] [Cited by in Crossref: 205] [Cited by in F6Publishing: 75] [Article Influence: 14.6] [Reference Citation Analysis]
186 Lubner MG, Jones D, Kloke J, Said A, Pickhardt PJ. CT texture analysis of the liver for assessing hepatic fibrosis in patients with hepatitis C virus. Br J Radiol 2019;92:20180153. [PMID: 30182750 DOI: 10.1259/bjr.20180153] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
187 Boursier J, Vergniol J, Guillet A, Hiriart J, Lannes A, Le Bail B, Michalak S, Chermak F, Bertrais S, Foucher J, Oberti F, Charbonnier M, Fouchard-hubert I, Rousselet M, Calès P, de Lédinghen V. Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease. Journal of Hepatology 2016;65:570-8. [DOI: 10.1016/j.jhep.2016.04.023] [Cited by in Crossref: 183] [Cited by in F6Publishing: 154] [Article Influence: 36.6] [Reference Citation Analysis]
188 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
189 Caillot F, Hiron M, Goria O, Gueudin M, Francois A, Scotte M, Daveau M, Salier JP. Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am J Pathol 2009;175:46-53. [PMID: 19477948 DOI: 10.2353/ajpath.2009.080850] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
190 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
191 Duarte-rojo A, Altamirano JT, Feld JJ. Noninvasive markers of fibrosis: key concepts for improving accuracy in daily clinical practice. Annals of Hepatology 2012;11:426-39. [DOI: 10.1016/s1665-2681(19)31456-5] [Cited by in Crossref: 31] [Article Influence: 3.4] [Reference Citation Analysis]
192 Fontana RJ, Bonkovsky HL, Naishadham D, Dienstag JL, Sterling RK, Lok AS, Su GL. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol. 2009;7:219-226. [PMID: 19068241 DOI: 10.1016/j.cgh.2008.10.034] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
193 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
194 Forns X. Diagnosis of liver fibrosis in 2008. Gastroentérologie Clinique et Biologique 2008;32:1-3. [DOI: 10.1016/s0399-8320(08)73988-5] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
195 Procopet B, Berzigotti A. New Tools for the Noninvasive Assessment of Cirrhosis. Curr Hepatology Rep. [DOI: 10.1007/s11901-014-0210-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
196 Gray J, Chattopadhyay D, Beale GS, Patman GL, Miele L, King BP, Stewart S, Hudson M, Day CP, Manas DM. A proteomic strategy to identify novel serum biomarkers for liver cirrhosis and hepatocellular cancer in individuals with fatty liver disease. BMC Cancer. 2009;9:271. [PMID: 19656391 DOI: 10.1186/1471-2407-9-271] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.9] [Reference Citation Analysis]
197 Anastasiou J, Alisa A, Virtue S, Portmann B, Murray-lyon I, Williams R. Noninvasive markers of fibrosis and inflammation in clinical practice: prospective comparison with liver biopsy. European Journal of Gastroenterology & Hepatology 2010;22:474-80. [DOI: 10.1097/meg.0b013e328332dd0a] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
198 Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Review of Gastroenterology & Hepatology 2019;13:361-74. [DOI: 10.1080/17474124.2019.1579641] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
199 Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C: Combination algorithms for liver fibrosis in HCV. Alimentary Pharmacology & Therapeutics 2012;35:92-104. [DOI: 10.1111/j.1365-2036.2011.04897.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
200 Kim BK, Han KH, Park JY, Ahn SH, Chon CY, Kim JK, Paik YH, Lee KS, Park YN, Kim DY. External validation of P2/MS and comparison with other simple non-invasive indices for predicting liver fibrosis in HBV-infected patients. Dig Dis Sci 2010;55:2636-43. [PMID: 19960253 DOI: 10.1007/s10620-009-1070-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
201 Berends MAM, Snoek J, de Jong EM, Van Krieken JH, de Knegt RJ, van Oijen MGH, van de Kerkhof PCM, Drenth JPH. Biochemical and biophysical assessment of MTX-induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan predicts the absence of significant liver fibrosis. Liver Int 2007;27:639-45. [DOI: 10.1111/j.1478-3231.2007.01489.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 50] [Article Influence: 3.6] [Reference Citation Analysis]
202 Fernandes FF, Ferraz ML, Andrade LE, Dellavance A, Terra C, Pereira G, Pereira JL, Campos F, Figueiredo F, Perez RM. Enhanced liver fibrosis panel as a predictor of liver fibrosis in chronic hepatitis C patients. J Clin Gastroenterol. 2015;49:235-241. [PMID: 24714186 DOI: 10.1097/mcg.0000000000000128] [Cited by in Crossref: 28] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
203 Zarski JP, Sturm N, Guechot J, Zafrani ES, Vaubourdolle M, Thoret S, Margier J, David-Tchouda S, Bosson JL. Contribution of the ELFG test in algorithms of non-invasive markers towards the diagnosis of significant fibrosis in chronic hepatitis C. PLoS One. 2013;8:e59088. [PMID: 23555619 DOI: 10.1371/journal.pone.0059088.] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
204 Adams LA. Biomarkers of liver fibrosis. J Gastroenterol Hepatol. 2011;26:802-809. [PMID: 21198831 DOI: 10.1111/j.1440-1746.2010.06612.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
205 Wang H, Zhou Y, Yan R, Ru GQ, Yu LL, Wang MS, Chen MJ. Development and validation of a model for staging hepatic fibrosis for chronic hepatitis B patients with E antigen-positive. Oncotarget 2017;8:98812-22. [PMID: 29228729 DOI: 10.18632/oncotarget.22003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
206 Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB, Park YN. Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci. 2011;56:555-563. [PMID: 20585981 DOI: 10.1007/s10620-010-1305-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
207 Park S, Kim HY, Kim H, Park JH, Kim JH, Kim KH, Kim W, Choi IS, Jung YJ, Kim JS. Changes in Noninvasive Liver Fibrosis Indices and Spleen Size During Chemotherapy: Potential Markers for Oxaliplatin-Induced Sinusoidal Obstruction Syndrome. Medicine (Baltimore). 2016;95:e2454. [PMID: 26765438 DOI: 10.1097/md.0000000000002454] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
208 Halfon P, Bourlière M, Pénaranda G, Cacoub P. Intérêt et limites des méthodes non invasives de prédiction de la fibrose hépatique au cours de l'hépatite C: une alternative à la biopsie hépatique. La Presse Médicale 2007;36:457-66. [DOI: 10.1016/j.lpm.2007.01.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
209 Wilde JT, Mutimer D, Dolan G, Millar C, Watson HG, Yee TT, Makris M. UKHCDO guidelines on the management of HCV in patients with hereditary bleeding disorders 2011. Haemophilia 2011;17:e877-83. [PMID: 21658165 DOI: 10.1111/j.1365-2516.2011.02585.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
210 Bourliere M, Penaranda G, Ouzan D, Renou C, Botta-fridlund D, Tran A, Rosenthal E, Wartelle-bladou C, Delasalle P, Oules V, Portal I, Castellani P, Lecomte L, Rosenthal-allieri MA, Halfon P. Optimized stepwise combination algorithms of non-invasive liver fibrosis scores including Hepascore in hepatitis C virus patients. Alimentary Pharmacology & Therapeutics 2008;28:458-67. [DOI: 10.1111/j.1365-2036.2008.03742.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
211 Shehab H, Elattar I, Elbaz T, Mohey M, Esmat G. CUFA algorithm: assessment of liver fibrosis using routine laboratory data. J Viral Hepat 2014;21:956-64. [DOI: 10.1111/jvh.12270] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
212 Kim TY, Kim JY, Sohn JH, Lee HS, Bang SY, Kim Y, Kim MY, Jeong WK. Assessment of Substantial Liver Fibrosis by Real-time Shear Wave Elastography in Methotrexate-Treated Patients With Rheumatoid Arthritis. J Ultrasound Med 2015;34:1621-30. [PMID: 26269292 DOI: 10.7863/ultra.15.14.10035] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
213 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
214 Alghamdi AS, Sanai FM, Ismail M, Alghamdi H, Alswat K, Alqutub A, Altraif I, Shah H, Alfaleh FZ; Saudi Association for the Study of Liver Diseases and Transplantation. SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol 2012;18 Suppl:S1-32. [PMID: 23006491 DOI: 10.4103/1319-3767.101155] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
215 Wu YM, Xu N, Hu JY, Xu XF, Wu WX, Gao SX, Zhu WJ, Wu WL, Shen XZ, Wang JY, Wu SD. A simple noninvasive index to predict significant liver fibrosis in patients with advanced schistosomiasis japonica. Parasitol Int 2013;62:283-8. [PMID: 23466574 DOI: 10.1016/j.parint.2013.02.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
216 Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: A comparative study. World J Gastroenterol 2010; 16(4): 501-507 [PMID: 20101779 DOI: 10.3748/wjg.v16.i4.501] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
217 Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourlière M, de Muret A, Sturm N, Hunault G, Penaranda G. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem. 2008;41:1368-1376. [PMID: 18655779 DOI: 10.1016/j.clinbiochem.2008.06.020] [Cited by in Crossref: 47] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
218 Busk TM, Bendtsen F, Nielsen HJ, Jensen V, Brünner N, Møller S. TIMP-1 in patients with cirrhosis: relation to liver dysfunction, portal hypertension, and hemodynamic changes. Scandinavian Journal of Gastroenterology 2014;49:1103-10. [DOI: 10.3109/00365521.2014.934910] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
219 Rossi E, Adams LA, Ching HL, Bulsara M, Macquillan GC, Jeffrey GP. High biological variation of serum hyaluronic acid and Hepascore, a biochemical marker model for the prediction of liver fibrosis. Clinical Chemistry and Laboratory Medicine 2013;51. [DOI: 10.1515/cclm-2012-0584] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
220 Cadranel JF, Lahmek P, Causse X, Bellaiche G, Bettan L, Fontanges T, Medini A, Henrion J, Chousterman M, Condat B. Epidemiology of chronic hepatitis B infection in France: risk factors for significant fibrosis--results of a nationwide survey. Aliment Pharmacol Ther. 2007;26:565-576. [PMID: 17661760 DOI: 10.1111/j.1365-2036.2007.03400.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
221 Bailly F, Ahmed SN, Pradat P, Trepo C. Management of nonresponsive hepatitis C. Expert Rev Anti Infect Ther 2010;8:379-95. [PMID: 20377334 DOI: 10.1586/eri.10.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
222 Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2:1344-1355. [PMID: 30411081 DOI: 10.1002/hep4.1237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 8.0] [Reference Citation Analysis]
223 Calès P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourlière M, de Muret A, Sturm N. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int. 2008;28:1352-1362. [PMID: 18492022 DOI: 10.1111/j.1478-3231.2008.01789.x] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 6.2] [Reference Citation Analysis]
224 Brouwer WP, van der Meer AJP, Boonstra A, Plompen EPC, Pas SD, de Knegt RJ, de Man RA, Ten Kate FJW, Janssen HLA, Hansen BE. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Viral Hepat. 2017;24:1023-1031. [PMID: 28544398 DOI: 10.1111/jvh.12727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
225 Boursier J, de Ledinghen V, Leroy V, Anty R, Francque S, Salmon D, Lannes A, Bertrais S, Oberti F, Fouchard-hubert I, Calès P. A stepwise algorithm using an at-a-glance first-line test for the non-invasive diagnosis of advanced liver fibrosis and cirrhosis. Journal of Hepatology 2017;66:1158-65. [DOI: 10.1016/j.jhep.2017.01.003] [Cited by in Crossref: 45] [Cited by in F6Publishing: 33] [Article Influence: 11.3] [Reference Citation Analysis]
226 Drescher HK, Weiskirchen S, Weiskirchen R. Current Status in Testing for Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Cells 2019;8:E845. [PMID: 31394730 DOI: 10.3390/cells8080845] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 22.5] [Reference Citation Analysis]
227 邵祥强, 肖华胜. 肝纤维化发病机制与临床诊断的研究进展. 世界华人消化杂志 2011; 19(3): 268-274 [DOI: 10.11569/wcjd.v19.i3.268] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
228 Cano A, Mariño Z, Millet O, Martínez-Arranz I, Navasa M, Falcón-Pérez JM, Pérez-Cormenzana M, Caballería J, Embade N, Forns X, Bosch J, Castro A, Mato JM. A Metabolomics Signature Linked To Liver Fibrosis In The Serum Of Transplanted Hepatitis C Patients. Sci Rep 2017;7:10497. [PMID: 28874799 DOI: 10.1038/s41598-017-10807-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
229 Zeremski M, Martinez A. Liver Disease and Fibrosis Assessment in Substance Use-Related Disorders. Clin Pharmacol Drug Dev 2017;6:164-8. [PMID: 28263455 DOI: 10.1002/cpdd.312] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
230 Calès P, Lainé F, Boursier J, Deugnier Y, Moal V, Oberti F, Hunault G, Rousselet MC, Hubert I, Laafi J. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol. 2009;50:165-173. [PMID: 18977552 DOI: 10.1016/j.jhep.2008.07.035] [Cited by in Crossref: 170] [Cited by in F6Publishing: 139] [Article Influence: 13.1] [Reference Citation Analysis]
231 Khalili H, Dayyeh BA, Friedman LS. Assessment of Liver Function in Clinical Practice. In: Ginès P, Kamath PS, Arroyo V, editors. Chronic Liver Failure. Totowa: Humana Press; 2011. pp. 47-76. [DOI: 10.1007/978-1-60761-866-9_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
232 European Association for Study of Liver. Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237-264. [PMID: 25911335 DOI: 10.1016/j.jhep.2015.04.006] [Cited by in Crossref: 918] [Cited by in F6Publishing: 784] [Article Influence: 153.0] [Reference Citation Analysis]
233 Lurie Y, Webb M, Cytter-Kuint R, Shteingart S, Lederkremer GZ. Non-invasive diagnosis of liver fibrosis and cirrhosis. World J Gastroenterol 2015; 21(41): 11567-11583 [PMID: 26556987 DOI: 10.3748/wjg.v21.i41.11567] [Cited by in CrossRef: 120] [Cited by in F6Publishing: 105] [Article Influence: 20.0] [Reference Citation Analysis]
234 Tachi Y, Hirai T, Toyoda H, Tada T, Hayashi K, Honda T, Ishigami M, Goto H, Kumada T. Predictive Ability of Laboratory Indices for Liver Fibrosis in Patients with Chronic Hepatitis C after the Eradication of Hepatitis C Virus. PLoS One 2015;10:e0133515. [PMID: 26214180 DOI: 10.1371/journal.pone.0133515] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
235 Calès P, Boursier J, de Lédinghen V, Halfon P, Bacq Y, Leroy V, Dib N, Oberti F, Sawadogo A, Rousselet M, Lunel F. Evaluation and improvement of a reliable diagnosis of cirrhosis by blood tests. Gastroentérologie Clinique et Biologique 2008;32:1050-60. [DOI: 10.1016/j.gcb.2008.09.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
236 Addolorato G, Abenavoli L, Dallio M, Federico A, Germani G, Gitto S, Leandro G, Loguercio C, Marra F, Stasi E. Alcohol associated liver disease 2020: A clinical practice guideline by the Italian Association for the Study of the Liver (AISF). Dig Liver Dis 2020;52:374-91. [PMID: 32001151 DOI: 10.1016/j.dld.2019.12.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
237 Stauber RE, Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007; 13(32): 4287-4294 [PMID: 17708599 DOI: 10.3748/wjg.v13.i32.4287] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
238 Qi X, Liu X, Zhang Y, Hou Y, Ren L, Wu C, Chen J, Xia C, Zhao J, Wang D, Zhang Y, Zhang X, Lin H, Wang H, Wang J, Cui Z, Li X, Deng H, Hou F, Peng Y, Wang X, Shao X, Li H, Guo X. Serum Liver Fibrosis Markers in the Prognosis of Liver Cirrhosis: A Prospective Observational Study. Med Sci Monit 2016;22:2720-30. [PMID: 27480906 DOI: 10.12659/msm.900441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
239 Mathurin P. [Alcohol and the liver]. Gastroenterol Clin Biol 2009;33:840-9. [PMID: 19729258 DOI: 10.1016/j.gcb.2009.06.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
240 Hernandez Roman J, Siddiqui MS. The role of noninvasive biomarkers in diagnosis and risk stratification in nonalcoholic fatty liver disease. Endocrinol Diabetes Metab 2020;3:e00127. [PMID: 33102796 DOI: 10.1002/edm2.127] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
241 Fontana RJ, Goodman ZD, Dienstag JL, Bonkovsky HL, Naishadham D, Sterling RK, Su GL, Ghosh M, Wright EC. Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology. 2008;47:789-798. [PMID: 18175357 DOI: 10.1002/hep.22099] [Cited by in Crossref: 127] [Cited by in F6Publishing: 116] [Article Influence: 9.8] [Reference Citation Analysis]
242 Török NJ. Recent advances in the pathogenesis and diagnosis of liver fibrosis. J Gastroenterol. 2008;43:315-321. [PMID: 18592147 DOI: 10.1007/s00535-008-2181-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
243 Guéchot J, Edrief S, Lasnier E, Küper R. Automated assay of hyaluronic acid in serum. Immuno-analyse & Biologie Spécialisée 2008;23:148-52. [DOI: 10.1016/j.immbio.2008.02.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
244 Younossi ZM. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: REVIEW: CURRENT MANAGEMENT OF NAFLD AND NASH. Alimentary Pharmacology & Therapeutics 2008;28:2-12. [DOI: 10.1111/j.1365-2036.2008.03710.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 93] [Article Influence: 7.8] [Reference Citation Analysis]
245 Iijima H, Tada T, Kumada T, Kobayashi N, Yoshida M, Aoki T, Nishimura T, Nakano C, Ishii A, Takashima T, Sakai Y, Aizawa N, Nishikawa H, Ikeda N, Iwata Y, Enomoto H, Ide Y, Hirota S, Fujimoto J, Nishiguchi S. Comparison of liver stiffness assessment by transient elastography and shear wave elastography using six ultrasound devices. Hepatol Res 2019;49:676-86. [DOI: 10.1111/hepr.13319] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
246 Fabris C, Smirne C, Toniutto P, Colletta C, Rapetti R, Minisini R, Falleti E, Leutner M, Pirisi M. Usefulness of six non-proprietary indirect markers of liver fibrosis in patients with chronic hepatitis C. Clin Chem Lab Med 2008;46:253-9. [PMID: 18324909 DOI: 10.1515/CCLM.2008.051] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
247 Bottero J, Lacombe K, Guéchot J, Serfaty L, Miailhes P, Bonnard P, Wendum D, Molina JM, Lascoux-Combe C, Girard PM. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol. 2009;50:1074-1083. [PMID: 19398234 DOI: 10.1016/j.jhep.2009.01.022] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
248 Das SK, Vasudevan DM. Genesis of hepatic fibrosis and its biochemical markers. Scand J Clin Lab Invest. 2008;68:260-269. [PMID: 18609066 DOI: 10.1080/00365510701668516] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
249 Xu S, Zhu W, Wan Y, Wang J, Chen X, Pi L, Lobo MK, Ren B, Ying Z, Morris M, Cao Q. Decreased Taurine and Creatine in the Thalamus May Relate to Behavioral Impairments in Ethanol-Fed Mice: A Pilot Study of Proton Magnetic Resonance Spectroscopy. Mol Imaging 2018;17:1536012117749051. [PMID: 29318932 DOI: 10.1177/1536012117749051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
250 Patouraux S, Bonnafous S, Voican CS, Anty R, Saint-Paul MC, Rosenthal-Allieri MA, Agostini H, Njike M, Barri-Ova N, Naveau S, Le Marchand-Brustel Y, Veillon P, Calès P, Perlemuter G, Tran A, Gual P. The osteopontin level in liver, adipose tissue and serum is correlated with fibrosis in patients with alcoholic liver disease. PLoS One 2012;7:e35612. [PMID: 22530059 DOI: 10.1371/journal.pone.0035612] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 6.4] [Reference Citation Analysis]
251 Bonnard P, Sombié R, Lescure FX, Bougouma A, Guiard-Schmid JB, Poynard T, Calès P, Housset C, Callard P, Le Pendeven C. Comparison of elastography, serum marker scores, and histology for the assessment of liver fibrosis in hepatitis B virus (HBV)-infected patients in Burkina Faso. Am J Trop Med Hyg. 2010;82:454-458. [PMID: 20207872 DOI: 10.4269/ajtmh.2010.09-0088] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 4.5] [Reference Citation Analysis]
252 Shaheen AAM, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterology 2007;102:2589-600. [DOI: 10.1111/j.1572-0241.2007.01466.x] [Cited by in Crossref: 233] [Cited by in F6Publishing: 219] [Article Influence: 16.6] [Reference Citation Analysis]
253 Anne M, Le Lan C, Monbet V, Boussard-plédel C, Ropert M, Sire O, Pouchard M, Jard C, Lucas J, Adam JL, Brissot P, Bureau B, Loréal O. Fiber evanescent wave spectroscopy using the mid-infrared provides useful fingerprints for metabolic profiling in humans. J Biomed Opt 2009;14:054033. [DOI: 10.1117/1.3253319] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
254 Guéchot J. [Noninvasive assessment of liver fibrosis in patients with chronic hepatitis virus C]. Presse Med. 2006;35:1317-1326. [PMID: 16969327 DOI: 10.1016/s0755-4982(06)74811-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
255 Meng F, Zheng Y, Zhang Q, Mu X, Xu X, Zhang H, Ding L. Noninvasive evaluation of liver fibrosis using real-time tissue elastography and transient elastography (FibroScan). J Ultrasound Med. 2015;34:403-410. [PMID: 25715361 DOI: 10.7863/ultra.34.3.403] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
256 Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, Leroy V, Fouchard-Hubert I, Bertrais S, Gallois Y. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2011;106:1255-1263. [PMID: 21468012 DOI: 10.1038/ajg.2011.100] [Cited by in Crossref: 66] [Cited by in F6Publishing: 63] [Article Influence: 6.6] [Reference Citation Analysis]
257 Carrión JA, Navasa M, Buti M, Torras X, Xiol X, Vergara M, Planas R, Solà R, Forns X. Elastografía hepática. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterología y Hepatología 2011;34:504-10. [DOI: 10.1016/j.gastrohep.2011.05.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
258 Wu H, Yan S, Wang G, Cui S, Zhang C, Zhu Q. von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis. Scand J Gastroenterol. 2015;50:1160-1169. [PMID: 25877661 DOI: 10.3109/00365521.2015.1037346] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
259 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 177] [Article Influence: 17.7] [Reference Citation Analysis]
260 Guha I, Rosenberg W. Noninvasive Assessment of Liver Fibrosis: Serum Markers, Imaging, and Other Modalities. Clinics in Liver Disease 2008;12:883-900. [DOI: 10.1016/j.cld.2008.07.010] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 1.7] [Reference Citation Analysis]
261 Maor Y, Calès P, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Pénaranda G, Bar-meir S, Martinowitz U, Halfon P. Improving estimation of liver fibrosis using combination and newer noninvasive biomarker scoring systems in hepatitis C-infected haemophilia patients. Haemophilia 2007;13:722-9. [DOI: 10.1111/j.1365-2516.2007.01548.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
262 Calès P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC. Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem. 2010;43:1315-1322. [PMID: 20713037 DOI: 10.1016/j.clinbiochem.2010.08.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
263 Liu T, Wang X, Karsdal MA, Leeming DJ, Genovese F. Molecular serum markers of liver fibrosis. Biomark Insights. 2012;7:105-117. [PMID: 22872786 DOI: 10.4137/bmi.s10009] [Cited by in Crossref: 76] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
264 Wang Y, Xu MY, Zheng RD, Xian JC, Xu HT, Shi JP, Li SB, Qu Y, Dong YW, Lu LG. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. Hepatol Res. 2013;43:441-451. [PMID: 23006433 DOI: 10.1111/j.1872-034x.2012.01094.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
265 Boursier J, Vergniol J, Sawadogo A, Dakka T, Michalak S, Gallois Y, Le Tallec V, Oberti F, Fouchard-Hubert I, Dib N. The combination of a blood test and Fibroscan improves the non-invasive diagnosis of liver fibrosis. Liver Int. 2009;29:1507-1515. [PMID: 19725892 DOI: 10.1111/j.1478-3231.2009.02101.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 77] [Article Influence: 7.3] [Reference Citation Analysis]
266 Taibi L, Boyd A, Bosselut N, Bottero J, Guéchot J, Lacombe K, Lasnier E, Baudin B, Vaubourdolle M. Diagnostic accuracy of the Coopscore© to predict liver fibrosis in human immunodeficiency virus/hepatitis B virus co-infection. Ann Clin Biochem 2018;55:236-43. [PMID: 28661201 DOI: 10.1177/0004563217707979] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
267 Hackl NJ, Bersch C, Feick P, Antoni C, Franke A, Singer MV, Nakchbandi IA. Circulating fibronectin isoforms predict the degree of fibrosis in chronic hepatitis C. Scand J Gastroenterol. 2010;45:349-356. [PMID: 20017652 DOI: 10.3109/00365520903490606] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
268 Almpanis Z, Demonakou M, Tiniakos D. Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol 2016;29:445-53. [PMID: 27708509 DOI: 10.20524/aog.2016.0046] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
269 Boursier J, Bacq Y, Halfon P, Leroy V, de Ledinghen V, de Muret A, Bourlière M, Sturm N, Foucher J, Oberti F, Rousselet MC, Calès P. Improved diagnostic accuracy of blood tests for severe fibrosis and cirrhosis in chronic hepatitis C: . European Journal of Gastroenterology & Hepatology 2009;21:28-38. [DOI: 10.1097/meg.0b013e32830cebd7] [Cited by in Crossref: 42] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
270 Cadranel JF, Nousbaum JB. [Current trends in liver biopsy indications in chronic liver diseases]. Presse Med 2012;41:1064-70. [PMID: 22425478 DOI: 10.1016/j.lpm.2012.01.034] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
271 Thabut D, Moreau R, Lebrec D. Noninvasive assessment of portal hypertension in patients with cirrhosis. Hepatology. 2011;53:683-694. [PMID: 21274889 DOI: 10.1002/hep.24129] [Cited by in Crossref: 94] [Cited by in F6Publishing: 82] [Article Influence: 9.4] [Reference Citation Analysis]
272 Crisan D, Radu C, Lupsor M, Sparchez Z, Grigorescu MD, Grigorescu M. Two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis C; results from a cohort of 446 patients. Hepat Mon. 2012;12:177-184. [PMID: 22550525 DOI: 10.5812/hepatmon.5106] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
273 Zhang ZQ, Huang LW, Chen YP, Wang P. Routine indexes for cirrhosis and significant fibrosis detection in patients with compensated chronic hepatitis B. Dig Liver Dis 2019;51:127-34. [PMID: 30076017 DOI: 10.1016/j.dld.2018.07.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
274 Zeng Q, Qiu J, Hong J, Li Y, Li S, Zou R, Huang P, Li B, Zheng Y, Lao X, Yuan Y. Hepatectomy for hepatocellular carcinoma patients with macronodular cirrhosis: . European Journal of Gastroenterology & Hepatology 2012;24:575-82. [DOI: 10.1097/meg.0b013e328351046a] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
275 Vali Y, Lee J, Boursier J, Spijker R, Verheij J, Brosnan MJ, Anstee QM, Bossuyt PM, Zafarmand MH, On Behalf Of The Litmus Systematic Review Team. FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis. J Clin Med 2021;10:2415. [PMID: 34072480 DOI: 10.3390/jcm10112415] [Reference Citation Analysis]
276 Mendes LC, Ferreira PA, Miotto N, Zanaga L, Gonçales E, Lazarini MS, Gonçales FL Júnior, Stucchi RS, Vigani AG. Transient elastography and APRI score: looking at false positives and false negatives. Diagnostic performance and association to fibrosis staging in chronic hepatitis C. Braz J Med Biol Res 2016;49:e5432. [PMID: 27533769 DOI: 10.1590/1414-431X20165432] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.6] [Reference Citation Analysis]
277 Van Dijk AM, Vali Y, Mak AL, Lee J, Tushuizen ME, Zafarmand MH, Anstee QM, Brosnan MJ, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analyses: Diagnostic Accuracy of FibroMeter Tests in Patients with Non-Alcoholic Fatty Liver Disease. J Clin Med 2021;10:2910. [PMID: 34209858 DOI: 10.3390/jcm10132910] [Reference Citation Analysis]
278 Stasi C, Milani S. Non-invasive assessment of liver fibrosis: Between prediction/prevention of outcomes and cost-effectiveness. World J Gastroenterol 2016; 22(4): 1711-1720 [PMID: 26819535 DOI: 10.3748/wjg.v22.i4.1711] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 33] [Article Influence: 8.2] [Reference Citation Analysis]
279 Ahmad W, Ijaz B, Gull S, Asad S, Khaliq S, Jahan S, Sarwar MT, Kausar H, Sumrin A, Shahid I. A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation. Virol J. 2011;8:53. [PMID: 21299910 DOI: 10.1186/1743-422x-8-53] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
280 Wu S, Ni Y, Liu L, Li H, Lu L, Wang J. Establishment and validation of a simple noninvasive model to predict significant liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2012;6:360-8. [DOI: 10.1007/s12072-011-9328-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
281 Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, Boisson RC, Bosson JL, Guyader D, Renversez JC, Bronowicki JP, Gelineau MC, Tran A, Trocme C, De Ledinghen V, Lasnier E, Poujol-Robert A, Ziegler F, Bourliere M, Voitot H, Larrey D, Rosenthal-Allieri MA, Fouchard Hubert I, Bailly F, Vaubourdolle M;  ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol. 2012;56:55-62. [PMID: 21781944 DOI: 10.1016/j.jhep.2011.05.024] [Cited by in Crossref: 142] [Cited by in F6Publishing: 126] [Article Influence: 14.2] [Reference Citation Analysis]
282 Goldberg DJ, Dodds K, Rychik J. Rare problems associated with the Fontan circulation. Cardiol Young 2010;20:113-9. [DOI: 10.1017/s1047951110001162] [Cited by in Crossref: 41] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
283 Ebrahimi H, Naderian M, Sohrabpour AA. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. Middle East J Dig Dis. 2016;8:166-178. [PMID: 27698966 DOI: 10.15171/mejdd.2016.29] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 5.2] [Reference Citation Analysis]
284 Mani H, Kleiner DE. Liver biopsy findings in chronic hepatitis B. Hepatology. 2009;49:S61-S71. [PMID: 19399798 DOI: 10.1002/hep.22930] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
285 Watanabe N, Ikeda H, Nakamura K, Ohkawa R, Kume Y, Aoki J, Hama K, Okudaira S, Tanaka M, Tomiya T. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C. J Clin Gastroenterol. 2007;41:616-623. [PMID: 17577119 DOI: 10.1097/01.mcg.0000225642.90898.0e] [Cited by in Crossref: 135] [Cited by in F6Publishing: 127] [Article Influence: 9.6] [Reference Citation Analysis]
286 Kim SG, Kim YS, Jung SW, Kim HK, Jang JY, Moon JH, Kim HS, Lee JS, Lee MS, Shim CS, Kim BS. The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic liver disease. Korean J Hepatol 2009;15:42. [DOI: 10.3350/kjhep.2009.15.1.42] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
287 Morra R, Munteanu M, Imbert-Bismut F, Messous D, Ratziu V, Poynard T. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev Mol Diagn 2007;7:481-90. [PMID: 17892356 DOI: 10.1586/14737159.7.5.481] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
288 Chrostek L, Panasiuk A. Liver fibrosis markers in alcoholic liver disease. World J Gastroenterol 2014; 20(25): 8018-8023 [PMID: 25009372 DOI: 10.3748/wjg.v20.i25.8018] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 4.3] [Reference Citation Analysis]
289 Lignon G, Boursier J, Delumeau S, Michalak-provost S, Lebigot J, Oberti F, Aubé C. Screening for significant chronic liver disease by using three simple ultrasound parameters. European Journal of Radiology 2015;84:1466-72. [DOI: 10.1016/j.ejrad.2015.05.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
290 Dhyani M, Anvari A, Samir AE. Ultrasound elastography: liver. Abdom Imaging 2015;40:698-708. [PMID: 25690689 DOI: 10.1007/s00261-015-0373-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
291 Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hepatol Int 2013;7:356-68. [PMID: 26201770 DOI: 10.1007/s12072-013-9439-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
292 Castera L. Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat. 2009;16:300-314. [PMID: 19254351 DOI: 10.1111/j.1365-2893.2009.01087.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 9.4] [Reference Citation Analysis]
293 Suk KT, Kim DY, Sohn KM, Kim DJ. Biomarkers of liver fibrosis. Adv Clin Chem 2013;62:33-122. [PMID: 24772665 DOI: 10.1016/b978-0-12-800096-0.00002-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
294 Veillon P, Gallois Y, Moal V, Fouchard-Hubert I, Charles I, Larcher F, Dib N, Boursier J, Oberti F, Laafi J, Guéchot J, Balan V, Calès P, Lunel-Fabiani F. Assessment of new hyaluronic acid assays and their impact on FibroMeter scores. Clin Chim Acta 2011;412:347-52. [PMID: 21075099 DOI: 10.1016/j.cca.2010.11.009] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
295 Chen J, Liu C, Chen H, Liu Q, Yang B, Ou Q. Study on noninvasive laboratory tests for fibrosis in chronic HBV infection and their evaluation. J Clin Lab Anal. 2013;27:5-11. [PMID: 23292737 DOI: 10.1002/jcla.21554] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
296 El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, ElAkel WA, Esmat G. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int. 2013;33:982-990. [PMID: 23509874 DOI: 10.1111/liv.12139] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
297 Enomoto M, Morikawa H, Tamori A, Kawada N. Noninvasive assessment of liver fibrosis in patients with chronic hepatitis B. World J Gastroenterol 2014; 20(34): 12031-12038 [PMID: 25232240 DOI: 10.3748/wjg.v20.i34.12031] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
298 Ritz L, Coulbault L, Lannuzel C, Boudehent C, Segobin S, Eustache F, Vabret F, Pitel AL, Beaunieux H. Clinical and Biological Risk Factors for Neuropsychological Impairment in Alcohol Use Disorder. PLoS One 2016;11:e0159616. [PMID: 27617840 DOI: 10.1371/journal.pone.0159616] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.6] [Reference Citation Analysis]
299 Nana J, Skaare K, Bosson JL, Leroy V, Asselah T, Adler M, Sturm N, Zarski JP. EASL-ALEH 2015 algorithm for the use of transient elastography in treatment-naive patients with hepatitis B: An independent validation. J Viral Hepat 2021;28:1169-76. [PMID: 34002927 DOI: 10.1111/jvh.13548] [Reference Citation Analysis]
300 Arora A, Sharma P. Non-invasive Diagnosis of Fibrosis in Non-alcoholic Fatty Liver Disease. J Clin Exp Hepatol. 2012;2:145-155. [PMID: 25755423 DOI: 10.1016/s0973-6883(12)60103-0] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
301 Enomoto H, Bando Y, Nakamura H, Nishiguchi S, Koga M. Liver fibrosis markers of nonalcoholic steatohepatitis. World J Gastroenterol 2015; 21(24): 7427-7435 [PMID: 26139988 DOI: 10.3748/wjg.v21.i24.7427] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
302 Nguyen-khac E, Chatelain D, Tramier B, Decrombecque C, Robert B, Joly J, Brevet M, Grignon P, Lion S, Le Page L, Dupas J. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Alimentary Pharmacology & Therapeutics 2008;28:1188-98. [DOI: 10.1111/j.1365-2036.2008.03831.x] [Cited by in Crossref: 145] [Cited by in F6Publishing: 120] [Article Influence: 11.2] [Reference Citation Analysis]
303 European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol. 2012;57:399-420. [PMID: 22633836 DOI: 10.1016/j.jhep.2012.04.004] [Cited by in Crossref: 400] [Cited by in F6Publishing: 351] [Article Influence: 44.4] [Reference Citation Analysis]
304 Hsieh YY, Tung SY, Lee K, Wu CS, Wei KL, Shen CH, Chang TS, Lin YH. Routine blood tests to predict liver fibrosis in chronic hepatitis C. World J Gastroenterol 2012; 18(8): 746-753 [PMID: 22371634 DOI: 10.3748/wjg.v18.i8.746] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
305 Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, Dauvois B, Prévot S, Ngo Y, Munteanu M. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology. 2009;49:97-105. [PMID: 19053048 DOI: 10.1002/hep.22576] [Cited by in Crossref: 183] [Cited by in F6Publishing: 159] [Article Influence: 15.3] [Reference Citation Analysis]
306 Arienti V, Aluigi L, Pretolani S, Accogli E, Polimeni L, Domanico A, Violi F. Ultrasonography (US) and non-invasive diagnostic methods for non-alcoholic fatty liver disease (NAFLD) and early vascular damage. Possible application in a population study on the metabolic syndrome (MS). Intern Emerg Med. 2012;7 Suppl 3:S283-S290. [PMID: 23073869 DOI: 10.1007/s11739-012-0824-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
307 Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta. 2010;411:86-91. [PMID: 19850017 DOI: 10.1016/j.cca.2009.10.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
308 Poynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V; LIDO Study Group; CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006;6:34. [PMID: 17096854 DOI: 10.1186/1471-230x-6-34] [Cited by in Crossref: 186] [Cited by in F6Publishing: 72] [Article Influence: 12.4] [Reference Citation Analysis]
309 Fitzpatrick E, Quaglia A, Vimalesvaran S, Basso MS, Dhawan A. Transient elastography is a useful noninvasive tool for the evaluation of fibrosis in paediatric chronic liver disease. J Pediatr Gastroenterol Nutr. 2013;56:72-76. [PMID: 22922372 DOI: 10.1097/mpg.0b013e31826f2760] [Cited by in Crossref: 83] [Cited by in F6Publishing: 30] [Article Influence: 10.4] [Reference Citation Analysis]
310 Utsunomiya T, Okamoto M, Wakiyama S, Hashimoto M, Fukuzawa K, Ezaki T, Aishima S, Yoshikawa Y, Hanai T, Inoue H, Barnard GF, Mori M. A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol 2007; 13(3): 383-390 [PMID: 17230606 DOI: 10.3748/wjg.v13.i3.383] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
311 De Bruyne RM, Fitzpatrick E, Dhawan A. Fatty liver disease in children: eat now pay later. Hepatol Int. 2010;4:375-385. [PMID: 20305757 DOI: 10.1007/s12072-009-9160-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
312 Ito K, Kuno A, Ikehara Y, Sugiyama M, Saito H, Aoki Y, Matsui T, Imamura M, Korenaga M, Murata K. LecT-Hepa, a glyco-marker derived from multiple lectins, as a predictor of liver fibrosis in chronic hepatitis C patients. Hepatology. 2012;56:1448-1456. [PMID: 22535703 DOI: 10.1002/hep.25815] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
313 Calès P, Boursier J, Chaigneau J, Lainé F, Sandrini J, Michalak S, Hubert I, Dib N, Oberti F, Bertrais S, Hunault G, Cavaro-Ménard C, Gallois Y, Deugnier Y, Rousselet MC. Diagnosis of different liver fibrosis characteristics by blood tests in non-alcoholic fatty liver disease. Liver Int 2010;30:1346-54. [PMID: 20666992 DOI: 10.1111/j.1478-3231.2010.02314.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
314 Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Bréchot MC. Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol. 2007;46:395-402. [PMID: 17156890 DOI: 10.1016/j.jhep.2006.09.020] [Cited by in Crossref: 95] [Cited by in F6Publishing: 91] [Article Influence: 6.3] [Reference Citation Analysis]
315 Delahaye J, Bazeries P, Lannes A, Lebigot J, Cartier V, Oberti F, Fouchard-Hubert I, Paisant A, Michalak-Provost S, Rousselet MC, Cales P, Boursier J, Aubé C. Doppler ultrasonography devices, including elastography, allow for accurate diagnosis of severe liver fibrosis. Eur J Radiol 2018;108:133-9. [PMID: 30396646 DOI: 10.1016/j.ejrad.2018.09.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
316 Schulz M, Tacke F. Identifying High-Risk NASH Patients: What We Know so Far. Hepat Med 2020;12:125-38. [PMID: 32982495 DOI: 10.2147/HMER.S265473] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
317 van Mierlo KM, Schaap FG, Dejong CH, Olde Damink SW. Liver resection for cancer: New developments in prediction, prevention and management of postresectional liver failure. J Hepatol. 2016;65:1217-1231. [PMID: 27312944 DOI: 10.1016/j.jhep.2016.06.006] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
318 Suh B, Park S, Shin DW, Yun JM, Yang HK, Yu SJ, Shin CI, Kim JS, Ahn E, Lee H, Park JH, Cho B. High liver fibrosis index FIB-4 is highly predictive of hepatocellular carcinoma in chronic hepatitis B carriers. Hepatology. 2015;61:1261-1268. [PMID: 25502481 DOI: 10.1002/hep.27654] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 9.3] [Reference Citation Analysis]
319 Poynard T, Morra R, Ingiliz P, Imbert-Bismut F, Thabut D, Messous D, Munteanu M, Massard J, Benhamou Y, Ratziu V. Biomarkers of liver fibrosis. Adv Clin Chem. 2008;46:131-160. [PMID: 19004189 DOI: 10.1016/s0065-2423(08)00404-6] [Cited by in Crossref: 46] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
320 Calès P, Veillon P, Konaté A, Mathieu E, Ternisien C, Chevailler A, Godon A, Gallois Y, Joubaud F, Hubert-Fouchard I. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem. 2008;41:10-18. [PMID: 17988658 DOI: 10.1016/j.clinbiochem.2007.08.009] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.7] [Reference Citation Analysis]